Moderna's melanoma therapy shows 83% response rate in trial

The 83% response rate in Moderna's melanoma therapy trial could enhance investor confidence and drive the stock higher in the short term. Technical indicators point to a bullish trend supported by the 20‑day moving average being above the 50‑day moving average and a 0.6% increase in the latest close. With an RSI of 56, the stock is not in over‑bought territory, suggesting the short‑term rally may be sustainable. The MACD is slightly above its signal line, indicating modest upward momentum. However, market sentiment and sector developments could increase volatility, so it is important to monitor positions closely.